Desmoid Tumors Market Expansion Outlook: $4.08 Billion by 2029 Forecast

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Desmoid Tumors Market Between 2025 And 2029?

The desmoid tumors market size has seen substantial growth over recent years. It is anticipated to expand from $2.97 billion in 2024 to $3.15 billion by 2025, achieving a compound annual growth rate (CAGR) of 6.3%. This past growth can be attributed to developments in medical imaging, advancements in genetic research and understanding, surgical innovations, heightened awareness and education, and patient advocacy.

The market for desmoid tumors is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $4.08 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.7%. Key drivers for this growth during the projected period include the emergence of targeted therapies, advancements in personalized medicine, broader international collaborations, regulatory clearances for innovative treatments, and patient-focused strategies. Significant trends observed during this forecast timeframe encompass progress in therapeutic methodologies, the development of precision medicine alongside biomarker identification, ongoing clinical trials and research efforts, the formation of multidisciplinary treatment teams, and increased patient advocacy and support.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13228&type=smp

What Are The Key Drivers Of Growth In The Desmoid Tumors Market?

The increasing incidence of cancer is anticipated to fuel the expansion of the desmoid tumor market in the future. Cancer encompasses a group of illnesses characterized by the uncontrolled proliferation and dissemination of abnormal cells within the body. Such cells have the capacity to invade adjacent tissues and organs, leading to damage. The global surge in cancer diagnoses has stimulated a need for efficacious and sophisticated chemotherapeutic solutions, thereby favorably impacting the desmoid tumor market. As an illustration, in May 2024, data from the National Cancer Institute, a US-based Federal government agency, indicated that approximately 2,001,140 new cancer cases are projected to be diagnosed in the U.S. in 2024, with 611,720 fatalities anticipated from the illness. Globally, 2022 saw nearly 20 million new cases and 9.7 million cancer-related deaths. Projections suggest that by 2040, the annual count of new cancer cases will escalate to 29.9 million, and cancer-related deaths will reach 15.3 million. Consequently, the escalating incidence of cancer is a key factor propelling the expansion of the desmoid tumor market.

What Are The Different Segment Classifications Within The Desmoid Tumors Market?

The desmoid tumorsmarket covered in this report is segmented –

1) By Treatment: Surgery; Radiation Therapy; Anti-Inflammatory Medication; Hormone Therapy; Chemotherapy; Novel Molecular-Targeted Therapy; Other Treatments

2) By Diagnosis: Biopsy; Electron Microscopic Examination; Immunohistochemical Analysis; Other Diagnosis

3) By End-User: Hospitals And Clinics; Specialty Centers; Other End-Users

Subsegments:

1) By Surgery: Wide Excision; Minimally Invasive Surgery

2) By Radiation Therapy: External Beam Radiation Therapy; Stereotactic Body Radiation Therapy

3) By Anti-Inflammatory Medication: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Corticosteroids

4) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors

5) By Chemotherapy: Traditional Chemotherapy Agents; Combination Chemotherapy

6) By Novel Molecular-Targeted Therapy: Tyrosine Kinase Inhibitors; Other Targeted Therapies

7) By Other Treatments: Watchful Waiting; Physical Therapy; Pain Management Strategies

How Are Emerging Market Trends Shaping The Desmoid Tumors Industry Landscape?

Leading companies operating in the desmoid tumors market are actively developing innovative drugs such as nirogacestat to better address the needs of their existing consumers for desmoid tumor treatment. Nirogacestat is an oral, small-molecule gamma-secretase inhibitor. For instance, in February 2023, SpringWorks Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had accepted and granted priority review for their new drug application (NDA) regarding nirogacestat for treating adults with desmoid tumors. This drug is thought to work by blocking the production of notch proteins, a mechanism that can lead to the death of tumor cells. Desmoid tumors are known to produce high levels of notch protein, which is believed to contribute to their growth. Furthermore, nirogacestat provides patients with a new treatment option that could potentially improve their outcomes.

Which Leading Companies Dominate The Desmoid Tumors Market Share?

Major companies operating in the desmoid tumors market report are Pfizer Inc., F.Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Abbott Laboratories, Amgen Inc., Stryker Corporation, Genome And Company, Vertex Pharmaceuticals Incorporated, Eisai Limited, Beckman Coulter Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., BeiGene Ltd., Janssen Biotech Inc., Ionis Pharmaceuticals Inc., Ayala Pharmaceuticals Inc., Blueprint Medicines Corporation, Xencor Inc., MacroGenics Inc., Debiopharm Group, Clovis Oncology Inc., Juno Therapeutics Inc., SpringWorks Therapeutics Inc., Loxo Oncology Inc., Mirati Therapeutics Inc., Iterion Therapeutics Inc., Recepta Pharmaceuticals Inc., Cellestia Biotech AG

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/desmoid-tumors-global-market-report

Which Regional Markets Are Contributing Most To The Desmoid Tumors Industry Expansion?

North America was the largest region in the desmoid tumors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the desmoid tumors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Desmoid Tumors Market Report:

https://www.thebusinessresearchcompany.com/customise?id=13228&type=smp

Browse Through More Reports Similar to the Global Desmoid Tumors Market 2025, By The Business Research Company

Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report

Tumor Infiltrating Lymphocytes Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/tumor-infiltrating-lymphocytes-global-market-report

Solid Tumor Cancer Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/solid-tumor-cancer-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795